Safety of a Single, Intravitreal Injection of 8.8M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 20, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Retinitis Pigmentosa
Interventions
BIOLOGICAL

human retinal progenitor cells

Single intravitreal injection of 8.8 million retinal progenitor cells (RPCs)

OTHER

Mock injection

Pressing the hub of a syringe with no needle against the eye to mimic intravitreal injection. Subjects randomized to the sham control group will undergo identical preparation as the active treatment group immediately prior to treatment, including application of anesthetics.

Trial Locations (6)

60304

NOT_YET_RECRUITING

Illinois Retina Associates, Oak Park

90074

RECRUITING

Retina-Vitreous Associates Medical Group, Beverly Hills

92093

RECRUITING

Shiley Eye Institute, UC San Diego, San Diego

92697

RECRUITING

Gavin Herbert Eye Institute, UC Irvine, Irvine

93309

RECRUITING

California Retina Consultants, Bakersfield

95825

NOT_YET_RECRUITING

Retina Consultants Medical Group, Sacramento

All Listed Sponsors
lead

jCyte, Inc

INDUSTRY